Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
Lipantil Micro 67 mg, capsules.
| Pharmaceutical Form |
|---|
|
Yellow, hard gelatin capsule. |
Each capsule contains 67 mg fenofibrate.
Excipients with known effect: each capsule contains 33.8 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fenofibrate |
Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. |
| List of Excipients |
|---|
|
Excipients: Lactose monohydrate Composition of the capsule shell: Gelatin |
Pack of 28, 56, 84, 90 capsules in blisters (PVC/Aluminium).
* Not all pack sizes may be marketed.
Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
PL 46302/0044
11 September 1997 / 10 September 2002
| Drug | Countries | |
|---|---|---|
| LIPANTIL | Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
